Oncology · 1 h ago
Adjuvant EGFR inhibitors linked to longer disease-free survival in uncommon-mutation NSCLC
A retrospective real-world study of 154 patients with completely resected non-small cell lung cancer (NSCLC) and major uncommon EGFR mutations found longer disease-free survival among those given adjuvant EGFR tyrosine kinase inhibitors (TKIs). The findings, including apparent differences by disease stage and TKI generation, are exploratory and require prospective evaluation.
- Retrospective study included 154 patients with uncommon EGFR mutations.
- Weighted 3-year DFS was 73.6% with TKIs and 53.0% without.
- Third-generation TKIs were associated with longer DFS than earlier agents.
- Findings are exploratory and require prospective confirmation.
Researchers retrospectively assessed patients with completely resected NSCLC carrying G719X, S768I, L861Q or compound major uncommon EGFR mutations who were treated from 2020 to 2023. Of 154 patients, 46 received adjuvant EGFR-TKIs and 108 did not. The primary endpoint was disease-free survival (DFS); baseline differences were addressed using inverse probability of treatment weighting. Median follow-up was 45.1 months.
After weighting, estimated 3-year DFS was 73.6% with adjuvant TKI therapy versus 53.0% without it (p=0.018). In multivariable analysis, TKI use was associated with lower risk of a DFS event (adjusted hazard ratio 0.42; p=0.006). The association appeared stronger in stage III disease (hazard ratio 0.26; p=0.006). Third-generation TKIs were associated with higher 3-year DFS than earlier-generation agents (83.7% vs 52.7%; p=0.010).
These observational results suggest a possible benefit in a rare molecular subgroup, but do not establish that TKIs caused the difference or identify an optimal treatment. The authors describe the findings as exploratory and call for prospective evaluation. The study was supported by Chinese public and institutional research funds; authors reported no competing interests.
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
BMC Medicine: Adjuvant EGFR-TKI therapy in completely resected non–small cell lung cancer with major uncommon EGFR mutations: a real-world study ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.